Eli Lilly, Compounders and Food and Drug Administration
Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look ...
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” fourth quarter 2024 investor ...
Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, ...
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback